Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : YEEHAW CANDIDATES -- Ignore unavailable to you. Want to Upgrade?

To: Galirayo who wrote (14906)	2/6/2006 2:56:21 PM
From: Galirayo	Read Replies (1) \| Respond to of 23958

[AMLN] Now one From Forbes .. Market Scan Amylin's Competitor Concerns For Byetta Seen Unwarranted Peter Kang, 02.06.06, 12:54 PM ET Amylin Pharmaceuticals Piper Jaffray said recent investor concerns regarding potential rivals to Amylin Pharmaceuticals' diabetes treatment Byetta were overblown and maintained an "outperform" rating on the specialty pharmaceutical firm. Investors have expressed concerns over the potential competitive pressure on Byetta sales from Exubera by Pfizer (nyse: PFE - news - people ), Acomplia by Sanofi-Aventis (nyse: SNY - news - people ) as well as a new class of DPP-IV inhibitors from the likes of Novartis (nyse: NVS - news - people ) and others, according to pharmaceutical analyst Thomas Wei. "Our hypothesis has been that the growth and size of the diabetes market will absorb multiple new entrants, both new drugs and new classes," the analyst wrote in a client note issued today. "We continue to believe that investors have underappreciated the sheer size and unmet need among patients failing Type 2 oral therapies." Wei noted that new drug introductions generally add to the growth in the diabetes market, citing three historical examples including Byetta's impact on Sanofi-Aventis' Lantus in June 2005. "In none of the three cases was there a decline in prescriptions of the incumbent drug and we would also argue that the incumbent growth trajectory was also unaffected," he said. The Piper Jaffray analyst maintained a price target of $50 on Amylin (nasdaq: AMLN - news - people ), saying the stock remains one of its top mid-cap picks in the sector. "We remain skeptical of the competition argument raised by the Amylin bears and continue to believe in the long-term potential of the Byetta franchise," Wei said. Byetta is co-marketed by Eli Lilly (nyse: LLY - news - people ). 1 of 1